Insmed, Inc. (NASDAQ:INSM) Given Consensus Recommendation of “Buy” by Analysts

Shares of Insmed, Inc. (NASDAQ:INSM) have been assigned a consensus rating of “Buy” from the twenty-four brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nineteen have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $207.5238.

INSM has been the subject of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and issued a $230.00 target price on shares of Insmed in a report on Monday, February 23rd. Truist Financial set a $205.00 target price on shares of Insmed in a research report on Monday, January 12th. Royal Bank Of Canada boosted their target price on shares of Insmed from $197.00 to $200.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Finally, Leerink Partners reissued an “outperform” rating on shares of Insmed in a report on Thursday, December 18th.

Insmed Trading Down 2.4%

Insmed stock opened at $140.13 on Friday. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. Insmed has a one year low of $60.40 and a one year high of $212.75. The stock has a market capitalization of $30.21 billion, a PE ratio of -21.86 and a beta of 1.13. The business’s fifty day moving average is $158.58 and its 200 day moving average is $165.58.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The business had revenue of $263.84 million during the quarter, compared to the consensus estimate of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.Insmed’s quarterly revenue was up 152.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.32) earnings per share. On average, sell-side analysts predict that Insmed will post -4.56 EPS for the current year.

Insider Transactions at Insmed

In other Insmed news, COO Roger Adsett sold 791 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $156.17, for a total value of $123,530.47. Following the transaction, the chief operating officer directly owned 106,810 shares of the company’s stock, valued at approximately $16,680,517.70. This trade represents a 0.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michael Alexander Smith sold 640 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $156.27, for a total value of $100,012.80. Following the sale, the insider owned 56,397 shares of the company’s stock, valued at approximately $8,813,159.19. This represents a 1.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 189,651 shares of company stock worth $31,784,545 in the last three months. 3.00% of the stock is owned by insiders.

Institutional Trading of Insmed

Several large investors have recently added to or reduced their stakes in INSM. Vanguard Group Inc. raised its position in Insmed by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after acquiring an additional 1,140,524 shares during the period. Darwin Global Management Ltd. grew its position in shares of Insmed by 2.3% during the 4th quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock valued at $3,644,274,000 after acquiring an additional 475,832 shares during the period. Capital International Investors increased its stake in shares of Insmed by 1.0% in the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock worth $1,087,830,000 after purchasing an additional 74,994 shares in the last quarter. State Street Corp increased its stake in shares of Insmed by 30.6% in the 4th quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after purchasing an additional 1,217,390 shares in the last quarter. Finally, Artisan Partners Limited Partnership raised its holdings in Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after purchasing an additional 1,623,342 shares during the period.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.